FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesActing Decisively
Members
PATIENT Receptivity to Direct-to-Patient Shipment in Clinical Trials - a GCSG sponsored study
Topic: Direct-to-Patient
White Paper
Members
Pelican webinar - Impact of COVID-19 on Cold Chain
Topics: Cold Chain, Supply Chain
Webinar
Free
